<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="131827">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01385774</url>
  </required_header>
  <id_info>
    <org_study_id>171102025;ZonMw</org_study_id>
    <secondary_id>09/285;METC AMC</secondary_id>
    <nct_id>NCT01385774</nct_id>
  </id_info>
  <brief_title>SUPER Study; SUPERvised Exercise or Angioplasty for Intermittent Claudication Due to an Iliac Artery Obstruction.</brief_title>
  <acronym>SUPER</acronym>
  <official_title>SUPERvised Exercise Therapy (SET) or Immediate Percutaneous Transluminal Angioplasty (PTA) for Intermittent Claudication (IC) in Patients With an Iliac Artery Obstruction: A Randomized Controlled Trial. SUPER Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ZonMw: The Netherlands Organisation for Health Research and Development</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of our study is to compare the clinical effectiveness and cost-effectiveness of
      two treatment strategies of Intermittent Claudication (IC) due to an iliac artery
      obstruction: to start with SUPERvised Exercise Therapy (SET) and deferred Percutaneous
      Transluminal Angioplasty (PTA) in case of SET failure, or immediate PTA.

      It is our hypothesis that PTA as first line treatment is more effective than SET as first
      line treatment with regard to maximum walking distance, quality of life and costs after one
      year.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Intermittent claudication (IC) is a manifestation of cardiovascular disease, reflected by a
      threefold increased risk in these patients of developing serious cardiovascular events.
      Treatment of patients with IC is aimed at secondary prevention of cardiovascular events by
      control of risk factors for atherosclerotic disease, and to improve walking distance and
      subsequently quality of life. Supervised Exercise Therapy (SET) and Percutaneous
      Transluminal Angioplasty (PTA) can effectively improve pain free walking distance, but the
      optimal choice of treatment, specifically in patients with an iliac artery stenosis or
      occlusion is unclear. PTA is attractive as initial therapy since PTA of the iliac arteries
      has an immediate effect and it is durable. There is a lack of evidence from randomized
      controlled trials (RCT) to define the optimal treatment strategy for patients with IC due to
      iliac artery lesions; first line treatment with SET and PTA in case of failure, or immediate
      iliac artery PTA.

      Purpose:

      To define the optimal treatment strategy of IC due to an iliac artery obstruction: To start
      with SET and deferred PTA in case of SET failure, or immediate PTA.

      Design:

      Multicenter randomized controlled trial.

      Patients:

      400 patients with IC due to an iliac artery stenosis or occlusion.

      Interventions:

      SET and PTA.

      Outcomes:

      Primary outcomes are quality of life (Qol) recorded with the disease specific VascuQol
      instrument and maximum walking distance on a standardized treadmill test with a speed of 3.2
      km/h at 10% incline after 1 year.

      Secondary outcomes are pain-free walking distance, generic Qol, functional status,
      complications, number of treatment failures and costs. Economic evaluation comprises a
      cost-effectiveness and cost-utility analysis from a societal perspective, with the costs per
      patient able to walk maximal, respectively the costs per Quality Adjusted Life-Year (QALY)
      as outcome measures.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2010</start_date>
  <completion_date type="Anticipated">April 2014</completion_date>
  <primary_completion_date type="Anticipated">November 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease specific Quality of Life</measure>
    <time_frame>12 months</time_frame>
    <description>Disease specific Quality of life (Qol) recorded with the disease specific VascuQol instrument 1 year after intervention.
The VascuQol will be completed at baseline and 1,6,12 months follow-up.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Walking Distance</measure>
    <time_frame>12 months</time_frame>
    <description>Maximum walking distance on a standardized treadmill test with a speed of 3.2 km/h at 10% incline measured 1 year after intervention.
The maximum walking distance will be assessed at baseline and 1,6,12 months follow-up.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Painfree Walking Distance</measure>
    <time_frame>12 months</time_frame>
    <description>Painfree walking distance on a standardized treadmill test with a speed of 3.2 km/h at 10% incline 1 year after intervention.
The painfree walking distance will be assessed at baseline and 1,6,12 months follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Status</measure>
    <time_frame>12 months</time_frame>
    <description>Functional status assessed by the AMC Linear Disability Score (ALDS) 1 year after intervention.
The ALDS will be completed at baseline and 1,6,12 months follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Generic Quality of Life</measure>
    <time_frame>12 months</time_frame>
    <description>Generic quality of life (Qol) recorded with the Short Form 36 (SF-36) and EQ-5D (former EuroQoL).
The SF-36 will be completed at baseline and 1,6,12 months follow-up. The EQ-5D will be completed at baseline, 1 week and 1,6,12 months follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications</measure>
    <time_frame>During 12 months</time_frame>
    <description>Complications related to both interventions during 12 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment failures</measure>
    <time_frame>During 12 months</time_frame>
    <description>A treatment failure is defined as crossover to the other treatment arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Costs</measure>
    <time_frame>During 12 months</time_frame>
    <description>Costs during 1 year.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Intermittent Claudication</condition>
  <condition>Peripheral Arterial Disease</condition>
  <arm_group>
    <arm_group_label>Intervention group: Angioplasty</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control: Supervised Exercise Therapy</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Percutaneous Transluminal Angioplasty</intervention_name>
    <description>The Percutaneous Transluminal Angioplasty (PTA) procedure will be performed by an experienced interventional radiologist using a conventional guide wire and balloon catheter technique. A stent will be placed in cases in which the residual mean pressure gradient is greater than 10 mmHg across the treated site or when more than 30% stenosis after the procedure is detected. All PTA patients are encouraged perform at least three walking sessions every day.</description>
    <arm_group_label>Intervention group: Angioplasty</arm_group_label>
    <other_name>Endovascular treatment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Supervised Exercise Therapy</intervention_name>
    <description>Supervised Exercise Therapy (SET) will take place in the hospital or community based according to the guidelines of the Dutch Society for Physiotherapists. The duration of the treatment will be at least 6 months and with a frequency of 2 times a week for at least 60 minutes and an intensity near maximum pain barrier (defined as pain of which it is not possible to be distracted). The frequency of the training will decrease after 3 months and the patients will receive homework, make a plan and keep a log of their exercise activities. Furthermore the program consists of walking pattern improvement and enhancement of endurance and strength. All SET patients are encouraged to perform at least three walking sessions every day on their own.</description>
    <arm_group_label>Control: Supervised Exercise Therapy</arm_group_label>
    <other_name>Conservative treatment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18 years or older;

          2. Disabling claudication as defined by surgeon based on patient's history;

          3. Ankle/Brachial Index (ABI) &lt; 0.9 or drop in ABI &gt; 0.15 after exercise test;

          4. Hemodynamic stenosis of the common or external iliac artery on Color Duplex Scanning
             (CDS) (PSV ratio ≥ 2.5 or EDV ≥ 0.6 m/s) or on Magnetic Resonance Angiography (MRA)
             or Computed Tomography Angiography (CTA)(&gt; 50% stenosis) or occlusion of the common
             or external iliac artery on CDS (PSV 0 m/s) or on MRA or CTA;

          5. Iliac artery lesion and a concomitant stenosis in the superficial femoral artery
             defined as stenosis &gt; 50% by CDS (PSV ratio ≥ 2.5 or EDV ≥ 0.6 m/s) or on MRA or CTA,
             or occlusion on CDS (PSV 0 m/s) or MRA or CTA;

          6. Lesion classified A, B or C according to the TASC (TransAtlantic Inter-Society
             Consensus) classification of aortoiliac lesions;

          7. Patient is able to walk at least 2 minutes on a treadmill at 3.2 km/h and 10%
             incline;

          8. The Maximum Walking Distance on a treadmill &lt; 300 meters.

        Exclusion Criteria:

          1. Life expectancy &lt; 3 months;

          2. Patient is unable to complete self-reported questionnaires (insufficiently reading or
             speaking the Dutch language, cognitive disorders, etc);

          3. Patient is unable to give informed consent;

          4. A documented contrast allergy;

          5. Pregnancy;

          6. Contra-indication for anticoagulant therapy;

          7. Duration of current complaints &lt; 3 months;

          8. Occlusion of the common femoral artery at the affected side;

          9. Patient participates in another study;

         10. Heart failure or Angina Pectoris NYHA III or IV. (NYHA III: Marked limitation of
             physical activity. Comfortable at rest, but less than ordinary activity causes
             fatigue, palpitation, or dyspnea; NYHA IV: Unable to carry out any physical activity
             without discomfort. Symptoms of cardiac insufficiency at rest. If any physical
             activity is undertaken, discomfort is increased);

         11. Patient previously received Supervised Exercise Therapy (SET) according to KNGF
             (Dutch Society for Physiotherapists) guidelines;

         12. Renal insufficiency (serum creatinin &gt; 150 micromol/l).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark JW Koelemay, M.D., Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jim A Reekers, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dink A Legemate, M.D.,Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shandra Bipat, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Franceline A Frans, M.D.</last_name>
    <phone>+31-205662936</phone>
    <email>info@superstudie.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mark JW Koelemay, M.D., Ph.D.</last_name>
    <phone>+31-205666654</phone>
    <email>m.j.koelemaij@amc.uva.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Flevoziekenhuis</name>
      <address>
        <city>Almere</city>
        <zip>1315 RA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>M Willems</last_name>
    </contact>
    <investigator>
      <last_name>M Willems</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sint Lucas Andreas Ziekenhuis</name>
      <address>
        <city>Amsterdam</city>
        <zip>1061 AE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>R C van Nieuwenhuizen</last_name>
    </contact>
    <investigator>
      <last_name>R C van Nieuwenhuizen</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>VU Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <zip>1081 HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>A WJ Hoksbergen</last_name>
    </contact>
    <investigator>
      <last_name>A WJ Hoksbergen</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Onze Lieve Vrouwe Gasthuis</name>
      <address>
        <city>Amsterdam</city>
        <zip>1091 AC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>A C Vahl</last_name>
    </contact>
    <investigator>
      <last_name>A C Vahl</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Academic Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Franceline A Frans, M.D.</last_name>
      <phone>+31-205662936</phone>
      <email>info@superstudie.nl</email>
    </contact>
    <contact_backup>
      <last_name>Mark JW Koelemay, M.D., Ph.D.</last_name>
      <phone>+31-205669111</phone>
      <email>m.j.koelemaij@amc.uva.nl</email>
    </contact_backup>
    <investigator>
      <last_name>Mark JW Koelemay, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jim A Reekers, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dink A Legemate, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shandra Bipat, Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>R HH Engelbert, Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>R J de Haan, Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>M GW Dijkgraaf, Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gelre ziekenhuizen</name>
      <address>
        <city>Apeldoorn</city>
        <zip>7334 DZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>H C Buscher</last_name>
    </contact>
    <investigator>
      <last_name>H C Buscher</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ziekenhuis Rijnstate</name>
      <address>
        <city>Arnhem</city>
        <zip>6815 AD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>M Reijnen</last_name>
    </contact>
    <investigator>
      <last_name>M Reijnen</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rode Kruis Ziekenhuis</name>
      <address>
        <city>Beverwijk</city>
        <zip>1942 LE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>A J de Nie, M.D.</last_name>
    </contact>
    <investigator>
      <last_name>A J de Nie</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Deventer Ziekenhuis</name>
      <address>
        <city>Deventer</city>
        <zip>7416 SE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>B HP Elsman</last_name>
    </contact>
    <investigator>
      <last_name>B HP Elsman</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kennemer Gasthuis</name>
      <address>
        <city>Haarlem</city>
        <zip>2035 RC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>E GJ Vermeulen</last_name>
    </contact>
    <investigator>
      <last_name>E GJ Vermeulen</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tergooiziekenhuizen</name>
      <address>
        <city>Hilversum</city>
        <zip>1213 XZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>E JF Hollander</last_name>
    </contact>
    <investigator>
      <last_name>E JF Hollander</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spaarne Ziekenhuis</name>
      <address>
        <city>Hoofddorp</city>
        <zip>2134 TM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>D Nio</last_name>
    </contact>
    <investigator>
      <last_name>D Nio</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Antonius Ziekenhuis</name>
      <address>
        <city>Nieuwegein</city>
        <zip>3435 CM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>J P de Vries</last_name>
    </contact>
    <investigator>
      <last_name>J P de Vries</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UMC St. Radboud</name>
      <address>
        <city>Nijmegen</city>
        <zip>6525 GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>J van der Vliet</last_name>
    </contact>
    <investigator>
      <last_name>J van der Vliet</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Waterland ziekenhuis</name>
      <address>
        <city>Purmerend</city>
        <zip>1441 RN</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Th AA van den Broek</last_name>
    </contact>
    <investigator>
      <last_name>Th AA van den Broek</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>May 2011</verification_date>
  <lastchanged_date>July 7, 2011</lastchanged_date>
  <firstreceived_date>June 28, 2011</firstreceived_date>
  <responsible_party>
    <name_title>Dr. M.J.W. Koelemay</name_title>
    <organization>Academic Medical Center</organization>
  </responsible_party>
  <keyword>Intermittent Claudication</keyword>
  <keyword>Percutaneous Transluminal Angioplasty</keyword>
  <keyword>Supervised Exercise Therapy</keyword>
  <keyword>Peripheral Arterial Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
    <mesh_term>Intermittent Claudication</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
